Hu-Lieskovan, S: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, Padmanee, Hu-Lieskovan, Siwen, Wargo, Jennifer A., Ribas, Antoni

Journal:

Year:

2017

Language:

english

File:

PDF, 1.37 MB

english, 2017

2

The EWS/FLI1 oncogenic transcription factor deregulates GLI1

Zwerner, J P, Joo, J, Warner, K L, Christensen, L, Hu-Lieskovan, S, Triche, T J, May, W A

Journal:

Year:

2007

Language:

english

File:

PDF, 600 KB

english, 2007

3

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirle

Journal:

Year:

2017

Language:

english

File:

PDF, 63 KB

english, 2017

4

EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients

Hu-Lieskovan, S., Vallbohmer, D., Zhang, W., Yang, D., Pohl, A., Labonte, M. J., Grimminger, P. P., Holscher, A. H., Semrau, R., Arnold, D., Dellas, K., Debucquoy, A., Haustermans, K., Machiels, J.-P.

Journal:

Clinical Cancer Research

Year:

2011

Language:

english

File:

PDF, 241 KB

english, 2011

5

Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges

Hu-Lieskovan, S., Robert, L., Homet Moreno, B., Ribas, A.

Journal:

Journal of Clinical Oncology

Year:

2014

Language:

english

File:

PDF, 194 KB

english, 2014

6

A Nanoparticle-Based Model Delivery System To Guide the Rational Design of Gene Delivery to the Liver. 2. In Vitro and In Vivo Uptake Results

Popielarski, Stephen R., Hu-Lieskovan, Siwen, French, Samuel W., Triche, Timothy J., Davis, Mark E.

Journal:

Bioconjugate Chemistry

Year:

2005

Language:

english

File:

PDF, 1.59 MB

english, 2005

7

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

Zhang, W., Winder, T., Ning, Y., Pohl, A., Yang, D., Kahn, M., Lurje, G., LaBonte, M. J., Wilson, P. M., Gordon, M. A., Hu-Lieskovan, S., Mauro, D. J., Langer, C., Rowinsky, E. K., Lenz, H.- J.

Journal:

Annals of Oncology

Year:

2011

Language:

english

File:

PDF, 133 KB

english, 2011

8

Exosomes as a predictor tool of acquired resistance to melanoma treatment

Goedert, Lucas, Koya, Richard, Hu-Lieskovan, Siwen, Ribas, Antoni

Journal:

BMC Proceedings

Year:

2014

Language:

english

File:

PDF, 249 KB

english, 2014

9

EWS-FLI1 Fusion Protein Up-regulates Critical Genes in Neural Crest Development and Is Responsible for the Observed Phenotype of Ewing's Family of Tumors

Hu-Lieskovan, S.

Journal:

Cancer Research

Year:

2005

Language:

english

File:

PDF, 1.02 MB

english, 2005

10

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma

Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., Ribas, A.

Journal:

Science Translational Medicine

Year:

2015

Language:

english

File:

PDF, 2.55 MB

english, 2015

11

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

Mok, Stephen, Tsoi, Jennifer, Koya, Richard C, Hu-Lieskovan, Siwen, West, Brian L, Bollag, Gideon, Graeber, Thomas G, Ribas, Antoni

Journal:

Year:

2015

Language:

english

File:

PDF, 2.01 MB

english, 2015

12

Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma

Hu-Lieskovan, S.

Journal:

Cancer Research

Year:

2005

Language:

english

File:

PDF, 1.82 MB

english, 2005

13

Excluding T Cells: Is β-Catenin the Full Story?

Hu-Lieskovan, Siwen, Homet Moreno, Blanca, Ribas, Antoni

Journal:

Year:

2015

Language:

english

File:

PDF, 179 KB

english, 2015

14

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

Robert, Lidia, Ribas, Antoni, Hu-Lieskovan, Siwen

Journal:

Seminars in Immunology

Year:

2016

Language:

english

File:

PDF, 1.10 MB

english, 2016

15

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirle

Journal:

Year:

2016

Language:

english

File:

PDF, 2.60 MB

english, 2016

16

Combined Treatment with Dabrafenib and Trametinib with Immune-stimulating Antibodies for BRAF Mutant Melanoma

Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni

Journal:

Year:

2015

Language:

english

File:

PDF, 3.02 MB

english, 2015

17

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, Jesse M., Garcia-Diaz, Angel, Shin, Daniel S., Escuin-Ordinas, Helena, Hugo, Willy, Hu-Lieskovan, Siwen, Torrejon, Davis Y., Abril-Rodriguez, Gabriel, Sandoval, Salemiz, Barthly, Lucas, Saco

Journal:

New England Journal of Medicine

Year:

2016

Language:

english

File:

PDF, 1.16 MB

english, 2016

18

Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells

Homet Moreno, B., Zaretsky, J. M., Garcia-Diaz, A., Tsoi, J., Parisi, G., Robert, L., Meeth, K., Ndoye, A., Bosenberg, M. W., Weeraratna, A. T., Graeber, T. G., Comin-Anduix, B., Hu-Lieskovan, S., Rib

Journal:

Cancer Immunology Research

Year:

2016

Language:

english

File:

PDF, 1.99 MB

english, 2016

19

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

Sachdev, J.C., Hu-Lieskovan, S., Patnaik, A., Eisenberg, P.D., Weise, A., Hutchinson, M.A., West, B., Gause, C., Tong, S., Ribas, A.

Journal:

Gynecologic Oncology

Year:

2016

Language:

english

File:

PDF, 114 KB

english, 2016

20

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure

Shin, Daniel, Garcia-Diaz, Angel, Zaretsky, Jesse, Escuin-Ordinas, Helena, Hu-Lieskovan, Siwen, Palaskas, Nicolaos J, Hugo, Willy, Komenan, Marie, Chmielowski, Bartosz, Cherry, Grace, Berent-Maoz, Bea

Journal:

Journal for ImmunoTherapy of Cancer

Year:

2015

Language:

english

File:

PDF, 251 KB

english, 2015

21

What does PD-L1 positive or negative mean?

Ribas, Antoni, Hu-Lieskovan, Siwen

Journal:

Journal of Experimental Medicine

Year:

2016

Language:

english

File:

PDF, 1.23 MB

english, 2016

22

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., Palaskas, N., Abril Rodriguez, G., Parisi, G.,

Journal:

Cancer Discovery

Year:

2016

Language:

english

File:

PDF, 9.79 MB

english, 2016

23

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Tolcher, Anthony W, Sznol, Mario, Hu-Lieskovan, Siwen, Papadopoulos, Kyriakos P., Patnaik, Amita, Rasco, Drew, Di Gravio, Donna, Huang, Bo, Gambhire, Dhiraj, Chen, Ying, Thall, Aron, Pathan, Nuzhat, S

Journal:

Clinical Cancer Research

Year:

2017

Language:

english

File:

PDF, 1.56 MB

english, 2017

24

New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone

Hu-Lieskovan, Siwen, Ribas, Antoni

Journal:

The Cancer Journal

Year:

2017

Language:

english

File:

PDF, 560 KB

english, 2017

25

1142PDSafety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb

Hamid, O., Ros, W., Thompson, J.A., Hu-Lieskovan, S., Eskens, F.A.L.M., Diab, A., Doi, T., Wasser, J., Spano, J-P., Rizvi, N.A., Angevin, E., Chiappori, A., Ott, P.A., Ganguly, B.J., Fleener, C., Dell

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 50 KB

english, 2017

26

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Ben Kong,, Munhoz, Rodrigo, Rapisuwon, Suthee, Gherardini, Pier Federico

Journal:

Year:

2018

Language:

english

File:

PDF, 8.93 MB

english, 2018

27

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

Nowicki, Theodore S., Hu-Lieskovan, Siwen, Ribas, Antoni

Journal:

The Cancer Journal

Year:

2018

Language:

english

File:

PDF, 160 KB

english, 2018

28

1207TiPAn open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder

Ott, P.A., Naing, A., Ramaswamy, G., Margolin, K., Moles, M., Gaynor, R., Goldstein, M.J., Hu-Lieskovan, S.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 50 KB

english, 2017

29

Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations

Evans, Elizabeth E, Hu-Lieskovan, Siwen, Bussler, Holm, Torno, Sebold, Mallow, Crystal, Reilly, Christine, Scrivens, Maria, Klimatcheva, Ekaterina, Winter, Laurie A, Kirk, Renee, Howell, Alan, Balch,

Journal:

Journal for ImmunoTherapy of Cancer

Year:

2015

Language:

english

File:

PDF, 253 KB

english, 2015

30

1183PSafety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF 06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC)

Hu-Lieskovan, S., Johnson, M., Braiteh, F.S., Grilley-Olson, J., Chou, J., Davda, J., Jin, B., Forgie, A., Rassam, D., Youssef, S.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 52 KB

english, 2017

31

1127OA personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

Ott, P A, Govindan, R, Naing, A, Friedlander, T W, Margolin, K, Lin, J J, Bhardwaj, N, Hellman, M D, Srinivasan, L, Greshock, J, Moles, M, Gaynor, R B, Goldstein, M J, Hu-Lieskovan, S

Journal:

Annals of Oncology

Year:

2018

Language:

english

File:

PDF, 92 KB

english, 2018

32

P2.09-05 Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001

Lisberg, A., Hu-Lieskovan, S., Grogan, T., Carroll, J., Shintaku, P., Han, M., Slamon, D., Dubinett, S., Goldman, J., Elashoff, D., Hellmann, M., Ribas, A., Garon, E.

Journal:

Journal of Thoracic Oncology

Year:

2018

Language:

english

File:

PDF, 144 KB

english, 2018

33

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

Fares, Charlene M., Van Allen, Eliezer M., Drake, Charles G., Allison, James P., Hu-Lieskovan, Siwen

Journal:

American Society of Clinical Oncology Educational Book

Year:

2019

Language:

english

File:

PDF, 768 KB

english, 2019

34

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

Allen, Clint T., Lee, Sunmin, Norberg, Scott M., Kovalovsky, Damian, Ye, Hong, Clavijo, Paul E., Hu-Lieskovan, Siwen, Schlegel, Richard, Schlom, Jeffrey, Strauss, Julius, Gulley, James L., Trepel, Jan

Journal:

Journal for ImmunoTherapy of Cancer

Year:

2019

File:

PDF, 1.84 MB

2019

35

Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer

Hu-Lieskovan, Siwen, Lisberg, Aaron, Zaretsky, Jesse M., Grogan, Tristan R, Rizvi, Hira, Wells, Daniel K., Carroll, James, Cummings, Amy, Madrigal, John, Jones, Benjamin, Gukasyan, Jacklin, Shintaku,

Journal:

Clinical Cancer Research

Year:

2019

Language:

english

File:

PDF, 1.35 MB

english, 2019

36

Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors

Johnson, Melissa L., Braiteh, Fadi, Grilley-Olson, Juneko E., Chou, Jeffrey, Davda, Jasmine, Forgie, Alison, Li, Ruifeng, Jacobs, Ira, Kazazi, Farhad, Hu-Lieskovan, Siwen

Journal:

Year:

2019

Language:

english

File:

PDF, 414 KB

english, 2019

37

Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer

Hu-Lieskovan, Siwen, Lisberg, Aaron, Zaretsky, Jesse M., Grogan, Tristan R, Rizvi, Hira, Wells, Daniel K., Carroll, James, Cummings, Amy, Madrigal, John, Jones, Benjamin, Gukasyan, Jacklin, Shintaku,

Journal:

Clinical Cancer Research

Year:

2019

File:

PDF, 1.35 MB

2019

38

Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?

Pal, Sumanta, Hu-Lieskovan, Siwen, Agarwal, Neeraj

Journal:

The Lancet Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

39

1184PPharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Hamid, O, Hu-Lieskovan, S, Ros, W, Diab, A, El-Khoueiry, A B, Thompson, J A, Eskens, F A, Spano, J-P, Angevin, E, Rizvi, N A, Wasser, J S, Ott, P A, Chiappori, A, Joh, T, Krupka, H I, Potluri, S, Wang

Journal:

Annals of Oncology

Year:

2018

File:

PDF, 77 KB

2018

40

Mechanisms of Resistance to PD-1 Checkpoint Blockade

Moser, Justin C., Hu-Lieskovan, Siwen

Journal:

Year:

2020

Language:

english

File:

PDF, 547 KB

english, 2020

41

Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges

McKean, William B., Moser, Justin C., Rimm, David, Hu-Lieskovan, Siwen

Journal:

American Society of Clinical Oncology Educational Book

Year:

2020

File:

PDF, 832 KB

2020

42

P860âResults from a combination of OX40 (PF-04518600) and 4â1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort

Chiappori, Alberto, Thompson, John, Eskens, Fredericus, Spano, Jean-Philippe, Doi, Toshihiko, Hamid, Omid, Diab, Adi, Rizvi, Naiyer, Hu-Lieskovan, Siwen, Ros, Willeke, Thomas, Jacob, Forgie, Alison, Y

Journal:

Journal for ImmunoTherapy of Cancer

Year:

2020

File:

PDF, 60 KB

2020